By Fineline Cube 
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China’s National Medical Products Administration (NMPA) has granted approval for Sotyktu (deucravacitinib) for use in adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy. This marks the second indication for the selective TYK2 inhibitor in China, following its initial approval for moderate-to-severe plaque psoriasis in October 2023.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New Indication Approval |
| Product | Sotyktu (deucravacitinib) – oral selective TYK2 allosteric inhibitor |
| New Indication | Active psoriatic arthritis (inadequate response/intolerance to DMARDs) |
| Approval Date | Week of June 16, 2026 |
| Previous China Approval | Moderate-to-severe plaque psoriasis (October 2023) |
Drug Profile & Mechanism of Action
- Molecule: Deucravacitinib – first-in-class, highly selective allosteric TYK2 inhibitor
- Target: Tyrosine kinase 2 (TYK2) – member of the JAK family involved in inflammatory signaling
- Innovation: Unique allosteric binding mechanism provides high selectivity, potentially improving safety profile compared to pan-JAK inhibitors
- Therapeutic Class: Represents a new class of small molecule oral targeted therapies for autoimmune conditions
- Dual Indication Status: First selective TYK2 allosteric inhibitor studied in clinical trials for both plaque psoriasis and psoriatic arthritis
Clinical Development & Evidence Base
| Indication | Approval Status (China) | Global Status |
|---|---|---|
| Moderate-to-Severe Plaque Psoriasis | Approved October 2023 | Approved in US, EU, Japan, and other major markets |
| Active Psoriatic Arthritis | Approved June 2026 | Phase III trials completed; regulatory reviews ongoing globally |
| Additional Indications Under Study | Lupus, inflammatory bowel disease | Various stages of clinical development |
The PsA approval is supported by robust Phase III clinical trial data demonstrating significant improvements in signs and symptoms of psoriatic arthritis, including joint pain, swelling, and physical function, compared to placebo.
Market Impact & Strategic Significance
- PsA Market Opportunity: China’s psoriatic arthritis market estimated at USD 800 million annually, with significant unmet need given limited treatment options beyond TNF inhibitors and conventional DMARDs
- Competitive Differentiation: Sotyktu represents the first oral targeted therapy specifically approved for PsA in China with a novel mechanism of action distinct from existing biologics and JAK inhibitors
- Commercial Synergy: Dual approval for both psoriasis and PsA enables comprehensive treatment approach for patients with both conditions, which co-occur in approximately 30% of psoriasis patients
- Revenue Potential: Analysts project peak annual sales of USD 1.2–1.8 billion globally across both indications by 2028, with China representing 15–20% of total revenue
BMS’s successful expansion of Sotyktu’s indications in China reinforces the company’s strategic focus on immunology and demonstrates the growing acceptance of novel targeted therapies in the Chinese market.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial expectations for Sotyktu (deucravacitinib). Actual results may differ due to risks including market adoption, competitive dynamics, reimbursement decisions, and execution of BMS’s commercial strategy.-Fineline Info & Tech